Emerging agents for treatment of the relapsed/refractory multiple myeloma: reports from the 56th American Society of Hematology annual meeting
10.3760/cma.j.issn.1009-9921.2015.03.007
- VernacularTitle:治疗复发、难治多发性骨髓瘤的新药:第56届美国血液学会年会报道
- Author:
Dongming ZHOU
;
Jinxiang FU
- Publication Type:Journal Article
- Keywords:
Multiple myeloma;
Relapsed;
Refractory;
American Society of Hematology annual meeting
- From:
Journal of Leukemia & Lymphoma
2015;24(3):152-156,160
- CountryChina
- Language:Chinese
-
Abstract:
Relapse/refractory multiple myeloma must be the main tough for the current clinical therapy,thus at the 56th American Society of Hematology annual meeting the latest treatment studies for the disease in 2014 were described in detail,including the joint application of drugs,the new drug clinical research,the safety and efficacy that could be inspiring.This chapter shows the mechanism of these new drug action,as well as the methods and side effects.
